Literature DB >> 26016846

Usefulness of MALDI-TOF Mass Spectrometry for Routine Identification of Candida Species in a Resource-Poor Setting.

Doudou Sow1, Bécaye Fall, Magatte Ndiaye, Bissoume Sambe Ba, Khadime Sylla, Roger Tine, Aminata Collé Lô, Annie Abiola, Boubacar Wade, Thérèse Dieng, Yémou Dieng, Jean Louis Ndiaye, Christophe Hennequin, Oumar Gaye, Babacar Faye.   

Abstract

BACKGROUND: Identification of fungal clinical isolates is essential for therapeutic management. In resource-limited settings, identification mostly relies on biochemical tests whose sensitivity and specificity are known to be insufficient for identification of closely related or newly described species. MALDI-TOF has been shown in favored countries to be a reliable and powerful tool for microorganism identification, including yeasts. The aim of this study was to compare MALDI-TOF with routine identification procedures in a resource-poor context.
METHODS: A total of 734 clinical specimens (502 vaginal swabs, 147 oral swabs, 61 bronchoalveolar lavage fluids and 24 stool samples) have been tested in the mycology unit of Fann Hospital, Dakar, Senegal. Strains isolated from culture were identified by both conventional phenotypic methods (germ tube formation and biochemical panels) and MALDI-TOF Saramis/VITEK MS, bioMérieux, France. In addition to comparing the final identification, we determined the time of obtaining the results and the cost for both approaches.
RESULTS: Overall, 218 (29.7 %) samples were positive for Candida. MALDI-TOF MS enabled the identification of 214 of the 218 strains isolated (98.1 %) at species level. Phenotypic approach yielded identification for 208 strains (95.4 %). Congruence between the tests was observed for 203 isolates. A discrepancy was observed for one isolate identified as Candida krusei with the phenotypic approach and Candida tropicalis with the MALDI-TOF. In addition, ten isolates identified at genus level by phenotypic methods were identified as C. glabrata (n = 8), C. tropicalis (n = 1) and C. parapsilosis (n = 1) by MALDI-TOF. The turnaround time for identification was <1 h using the MALDI-TOF compared to our routine procedures (48 h). The overall cost (reagents + expendables) per isolate was at 1.35<euro> for the MALDI-TOF MS.
CONCLUSION: MALDI-TOF clearly outperformed the diagnosis capacities of phenotypic methods by reducing the delay of results and giving accurate identification at species level. Moreover, this approach appears to be cost-effective and should be implemented especially in resource-poor context.

Entities:  

Mesh:

Year:  2015        PMID: 26016846     DOI: 10.1007/s11046-015-9905-2

Source DB:  PubMed          Journal:  Mycopathologia        ISSN: 0301-486X            Impact factor:   2.574


  27 in total

1.  Evaluation of matrix-assisted laser desorption ionization-time of flight mass spectrometry for identification of clinically important yeast species.

Authors:  Lindsay G Stevenson; Steven K Drake; Yvonne R Shea; Adrian M Zelazny; Patrick R Murray
Journal:  J Clin Microbiol       Date:  2010-07-28       Impact factor: 5.948

2.  Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study.

Authors:  Kevin W Garey; Milind Rege; Manjunath P Pai; Dana E Mingo; Katie J Suda; Robin S Turpin; David T Bearden
Journal:  Clin Infect Dis       Date:  2006-05-16       Impact factor: 9.079

3.  Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality.

Authors:  Matthew Morrell; Victoria J Fraser; Marin H Kollef
Journal:  Antimicrob Agents Chemother       Date:  2005-09       Impact factor: 5.191

4.  Improved clinical laboratory identification of human pathogenic yeasts by matrix-assisted laser desorption ionization time-of-flight mass spectrometry.

Authors:  O Bader; M Weig; L Taverne-Ghadwal; R Lugert; U Gross; M Kuhns
Journal:  Clin Microbiol Infect       Date:  2010-12-03       Impact factor: 8.067

5.  Identification of medically important yeast species by sequence analysis of the internal transcribed spacer regions.

Authors:  Shiang Ning Leaw; Hsien Chang Chang; Hsiao Fang Sun; Richard Barton; Jean-Philippe Bouchara; Tsung Chain Chang
Journal:  J Clin Microbiol       Date:  2006-03       Impact factor: 5.948

6.  First molecular method for discriminating between Candida africana, Candida albicans, and Candida dubliniensis by using hwp1 gene.

Authors:  Orazio Romeo; Giuseppe Criseo
Journal:  Diagn Microbiol Infect Dis       Date:  2008-07-21       Impact factor: 2.803

7.  Epidemiology, antifungal susceptibility, and pathogenicity of Candida africana isolates from the United Kingdom.

Authors:  Andrew M Borman; Adrien Szekely; Chistopher J Linton; Michael D Palmer; Phillipa Brown; Elizabeth M Johnson
Journal:  J Clin Microbiol       Date:  2013-01-09       Impact factor: 5.948

8.  Prospective evaluation of a matrix-assisted laser desorption ionization-time of flight mass spectrometry system in a hospital clinical microbiology laboratory for identification of bacteria and yeasts: a bench-by-bench study for assessing the impact on time to identification and cost-effectiveness.

Authors:  K E Tan; B C Ellis; R Lee; P D Stamper; S X Zhang; K C Carroll
Journal:  J Clin Microbiol       Date:  2012-08-01       Impact factor: 5.948

9.  Candida colonisation in asymptomatic HIV patients attending a tertiary hospital in Benin City, Nigeria.

Authors:  Newton O Esebelahie; Ifeoma B Enweani; Richard Omoregie
Journal:  Libyan J Med       Date:  2013-03-18       Impact factor: 1.743

10.  Surveillance study of species distribution, antifungal susceptibility and mortality of nosocomial candidemia in a tertiary care hospital in China.

Authors:  Chun-fang Ma; Fang-qiu Li; Li-ning Shi; Yu-an Hu; Ying Wang; Mei Huang; Qian-qian Kong
Journal:  BMC Infect Dis       Date:  2013-07-22       Impact factor: 3.090

View more
  7 in total

Review 1.  Mass spectrometry in research laboratories and clinical diagnostic: a new era in medical mycology.

Authors:  Hasti Kamali Sarvestani; Alireza Ramandi; Muhammad Ibrahim Getso; Taraneh Razavyoon; Javad Javidnia; Miaad Banay Golrizi; Ali-Akbar Saboor-Yaraghi; Saham Ansari
Journal:  Braz J Microbiol       Date:  2022-03-28       Impact factor: 2.214

2.  Characterization of the fungal flora of dolo, a traditional fermented beverage of Burkina Faso, using MALDI-TOF mass spectrometry.

Authors:  Bamba Sanata; Zida Adama; Sangaré Ibrahim; Sondo Apoline; Cissé Mamoudou; Sirima Constant; Guiguemdé T Robert; Hennequin Christophe
Journal:  World J Microbiol Biotechnol       Date:  2017-08-29       Impact factor: 3.312

Review 3.  Matrix-Assisted Laser Desorption Ionization Time-of-Flight for Fungal Identification.

Authors:  Anna F Lau
Journal:  Clin Lab Med       Date:  2021-04-24       Impact factor: 2.172

Review 4.  An Update on Candida tropicalis Based on Basic and Clinical Approaches.

Authors:  Diana L Zuza-Alves; Walicyranison P Silva-Rocha; Guilherme M Chaves
Journal:  Front Microbiol       Date:  2017-10-13       Impact factor: 5.640

5.  Antifungal Susceptibility of Candida Species Isolated from Horticulturists with Onychomycosis in Piauí, Brazil.

Authors:  Mitra Mobin; Maria Walderez Szeszs; Juliana Possatto Takahashi; Marilena Martins; Daise Damaris Carnietto de Hippólito; Jhonatas Cley Santos Porto; João Batista Teles; Sidney Gonçalo de Lima; Marcia de Souza Carvalho Melhem
Journal:  Iran J Public Health       Date:  2018-12       Impact factor: 1.429

6.  Culturomics and Amplicon-based Metagenomic Approaches for the Study of Fungal Population in Human Gut Microbiota.

Authors:  Ibrahim Hamad; Stéphane Ranque; Esam I Azhar; Muhammad Yasir; Asif A Jiman-Fatani; Hervé Tissot-Dupont; Didier Raoult; Fadi Bittar
Journal:  Sci Rep       Date:  2017-12-01       Impact factor: 4.379

7.  Identification of nine cryptic species of Candida albicans, C. glabrata, and C. parapsilosis complexes using one-step multiplex PCR.

Authors:  Amir Arastehfar; Wenjie Fang; Weihua Pan; Wanqing Liao; Liang Yan; Teun Boekhout
Journal:  BMC Infect Dis       Date:  2018-09-25       Impact factor: 3.090

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.